Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA To Miss Review Deadline For PPD’s Alogliptin NDA

By Pharmaceutical Processing | October 10, 2008

PPD, Inc. has announced that Takeda Pharmaceutical Company Limited reported that Takeda Global Research and Development Center, Inc., a wholly owned U.S. subsidiary, has received notification that the FDA will not be able to complete its review of the alogliptin new drug application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of October 27, 2008. Takeda stated that in its most recent discussion with the FDA, the agency indicated that due to internal resource constraints it would not be able to complete the alogliptin review by the PDUFA date. Although Takeda said the FDA did not provide any guidance on when a review might be completed, Takeda indicated that it remains confident in alogliptin’s potential as a new treatment option for people suffering from type 2 diabetes and reiterated that it will work with the FDA as the agency continues this NDA review. As a result of this notification, PPD does not anticipate the FDA will complete its review of the alogliptin NDA by the end of 2008. Thus, PPD does not expect to receive the $25.0 million alogliptin NDA approval milestone in the fourth quarter of 2008. Alogliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor discovered by Takeda’s wholly owned U.S. subsidiary, Takeda San Diego, Inc. In December 2007, Takeda submitted its NDA for alogliptin for the treatment of type 2 diabetes.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards